stockportfolio.pro
Stocks / ALNY vs ZTS
ALNY vs ZTS
Alnylam Pharmaceuticals, Inc. and Zoetis Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Alnylam Pharmaceuticals, Inc. (ALNY) | Zoetis Inc. (ZTS) | |
|---|---|---|
| Market cap | $38.9B | $33.5B |
| Revenue (latest FY) | $3.71B | $9.47B |
| Net income (latest FY) | $313.75M | $2.67B |
| Revenue growth (5y CAGR) | 49.8% | 7.2% |
| Net margin | 8.4% | 28.2% |
| Return on equity | 39.8% | 78.3% |
| P/E ratio | 73.0 | 13.1 |
| Dividend yield | — | 2.7% |
| Profitable years (of last 10) | 1 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ALNY — free Open ZTS — freeFrequently asked questions
Which is bigger, ALNY or ZTS?
Alnylam Pharmaceuticals, Inc. is larger by market capitalization — $38.9B versus $33.5B.
Which grows faster, ALNY or ZTS?
Over the last five fiscal years, Alnylam Pharmaceuticals, Inc. grew revenue faster — 49.8%/yr versus 7.2%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.